Computational Healthcare

Imagine a world where drugs are tested not on animals but on actual human cells before they reach clinical trials. Imagine that every patient could receive therapeutics that are proven to be effective on that particular patient, not just the general population. This could save years of trial and error and patient suffering. We’re thrilled to back SUN Biosciences, who are building the foundations for this future by standardising organoid culture to build a single source of biological truth for drug testing, development and application. Their unique technology solves some of the core issues that have been holding organoids back.

Molecule is a digital interface matching supply and demand for biotech and pharma assets. Most of those assets currently live inside universities, small biotech companies, and, increasingly, AI drug discovery companies. Molecule crawls and lists research projects and enriches the data over time (this is increasingly done by researchers themselves who "claim" and develop their profiles). Interested investors can search pre-vetted projects depending on their therapeutic area, clinical stage and type of project.

Avi Medical plans to operate modern and efficient medical centers to optimise and control the process of primary care, end-to-end. The medical centers are utilising state-of-the art digital infrastructure with an app for patients and a modern software stack for doctors. This brings process efficiency, a welcoming user experience before, during and after GP visits, 24/7 access to medical support and accurate diagnosis and treatments to the patients.

Heidi is building the gateway for patients anywhere in the world to get the care they need rapidly, easily and cheaply while providing every doctor with the tools to provide modern care that is safe, productive and deeply satisfying.

There are two parts to the Flow Bio system, a sensor made up of electrodes and micro-fluidics channels (this part is disposable), and a shell that holds the battery, electronics, RAM etc. Data is then displayed on a connected app where FlowBio's own data will be displayed and can be connected to other 3rd party data. The first biomarkers will be potassium, sodium and sweat rate to provide the most comprehensive and real-time view into hydration status.

Exakt Health's mobile app leads users through "self-diagnosis" for standard sports injuries and offers customised professional physiotherapy plans for different conditions. Exakt will first focus on running-related injuries, prior to expanding to other rehabilitation segments. The app provides free and easy access to sports physiotherapists and doctors' expertise through modern technology. No commute. No waiting rooms.

Hello Inside provides the user with intelligent, personalised insights based on their food intake and glycemic response (the effect that food or meal has on blood sugar levels after consumption - something that differs for each of us). The Continuous Glucose Monitoring patch has a small, sub-cutaneous needle which detects the glucose levels in blood and transmits the readings via bluetooth to any connected device. Hello Inside will leverage this technology to build a personalised health platform for consumers.

With a strong foundation of fundamental research, Inventia has developed a proprietary platform encompassing drop-on-demand bio-printing technology, an expanding library of printable matrices and custom protocols for specific applications. The RASTRUM platform is now available to enable efficient and powerful bio-printing of 3D cell-based assays for biomedical research.

At Enveda, they are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. This platform harnesses nature's complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics. Enveda is starting a movement to create the next generation of small molecule therapeutics.

The future of mRNA technology is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible Biotechnologies is on a journey to solve this problem by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA on demand.

RevoNA holds huge potential in treating currently ‘undruggable’ diseases by overcoming the challenges associated with targeting RNA. Conventional approaches are slow and costly, limited by inadequate R&D tools and RNA complexity, resulting in a shortage of crucial data in the field. Next-generation technologies are essential to unlocking the necessary data to drive RNA Drug discovery forward. RevoNA’s innovative solution integrates a novel high-throughput RNA biological platform, that rapidly amasses premium RNA datasets enriched with diverse information. These comprehensive datasets feed a complementary AI prediction engine build, that will enable RevoNA to significantly reduce the time-to-market for RNA-targeted drugs and make discovery affordable at scale.

LEVY Health is the first Clinical Decision Support Software (CDSS) that enables healthcare providers to expand their scope of practice to treat more patients. Aligned with clinical guidelines, our software serves as a valuable ally for clinical staff and OB-GYNs. It takes charge of pre-screening, lab ordering and analysis, triaging, and result interpretation. By automizing those responsibilities, our software offers tailored diagnostic insights and treatment recommendations, ensuring a more efficient and comprehensive approach to patient care. This broadens access to reproductive care by empowering providers to build more families.